---
title: "Boston Scientific (BSX): CHAMPION AF Trial Poised to Strengthen Watchman Evidence, Broaden Adoption, and Support Buy Rating"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278322576.md"
description: "Boston Scientific (BSX) received a Buy rating from analyst Josh Jennings of TD Cowen, with a price target of $100. The rating is supported by the promising CHAMPION AF trial, which is the largest randomized study of left atrial appendage closure, involving around 3,000 patients. Jennings believes the trial's results will enhance the evidence for the Watchman device, increase its adoption, and strengthen Boston Scientific's market position. UBS also maintains a Buy rating with a $120 price target."
datetime: "2026-03-09T03:15:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278322576.md)
  - [en](https://longbridge.com/en/news/278322576.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278322576.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278322576.md) | [繁體中文](https://longbridge.com/zh-HK/news/278322576.md)


# Boston Scientific (BSX): CHAMPION AF Trial Poised to Strengthen Watchman Evidence, Broaden Adoption, and Support Buy Rating

Boston Scientific, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $100.00 price target.

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Josh Jennings has given his Buy rating due to a combination of factors that center on the strength of Boston Scientific’s Watchman franchise and the pivotal CHAMPION AF trial. He views the independent clinician’s detailed assessment and optimistic outlook for CHAMPION AF—projecting non‑inferiority versus DOACs on the main composite endpoint and an advantage on bleeding—as a strong external validation of his thesis on BSX.

Jennings also highlights that CHAMPION AF is the largest randomized left atrial appendage closure study to date, with roughly 3,000 patients, far exceeding the size of earlier PROTECT AF, PREVAIL, and even OPTION datasets. In his analysis, the unprecedented scale, breadth of endpoints, and expected positive readout are likely to elevate the evidence base for Watchman, expand its clinical adoption, and reinforce Boston Scientific’s competitive position, collectively supporting a favorable risk‑reward profile for the stock.

In another report released on March 5, UBS also reiterated a Buy rating on the stock with a $120.00 price target.

### Related Stocks

- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [Boston Scientific Corporation (BSX.US)](https://longbridge.com/en/quote/BSX.US.md)

## Related News & Research

- [Boston Scientific (BSX) Gets a Hold from Erste Group](https://longbridge.com/en/news/281570952.md)
- [Needham & Company LLC Reaffirms Buy Rating for Boston Scientific (NYSE:BSX)](https://longbridge.com/en/news/281016414.md)
- [Boston Scientific receives FDA clearance for the Asurys™ Fluid Management System | BSX Stock News](https://longbridge.com/en/news/281002542.md)
- [Boston Scientific Unveils “Practice-Transforming” Trial Data for PE and AF at ACC Conference Call](https://longbridge.com/en/news/280889466.md)
- [Buy Rating on Boston Scientific’s Watchman FLX Backed by Champion Trial Success and Accelerating LAAC Market Growth](https://longbridge.com/en/news/280945768.md)